BackEupraxia Pharmaceuticals Overview

Eupraxia Pharmaceuticals Research & Development

Get informed when a big investor buys or sells

+ Follow

Quarterly R&D Expenses

$10.95M
184.42% YoY

As of Mar 31, 2026

Annual R&D Expenses (TTM)

$33.17M
110.55% YoY

Trailing 12 months ending Mar 31, 2026

Average R&D Expenses (Comparison Companies)

Research & Development History

Research & Development Comparison

Annual Research & Development Growth Rate (%)

Annual Research & Development Growth (Absolute)

Eupraxia Pharmaceuticals (EPRX) FAQ

Stockcircle tracks research & development for Eupraxia Pharmaceuticals (EPRX), including historical charts and peer comparisons when data is available. Check back as new filings are published, or open the stock overview for a broader fundamental snapshot.

This Research & Development page is built for Eupraxia Pharmaceuticals's historical R&D spending trend and peer context. When enough reporting periods are on file, the charts below visualize how the metric has moved over time.

Use R&D spending as one input alongside growth, profitability, valuation, and ownership activity. Stockcircle links related metric pages and the main EPRX overview so you can move from this figure to the surrounding analysis quickly.